Effects of denosumab on bone mineral density and bone turnover markers in rheumatoid arthritis patients switching from bisphosphonates

Journal of Experimental Orthopaedics

Makoto Inoue¹  Yukio Yonemoto²  Hirotaka Chikuda²  Chisa Okura²  Takahito Suto²  Masahiro Tachibana²  Koichi Okamura²  Hideo Sakane³  Tetsuya Kaneko³ 

[1] Department of Orthopaedic Surgery and Rheumatology, Inoue Hospital;Department of Orthopaedic Surgery, Gunma University Graduate School of Medicine;Department of Orthopaedic Surgery, Japan Redcross Society Fukaya Red Cross Hospital;

关键词: Osteoporosis;    Denosumab;    Bisphosphonate;    Rheumatoid arthritis;    Fragility fractures;   

DOI  :  10.1186/s40634-019-0211-7

来源: DOAJ

【 摘 要 】

Abstract Background To compare the efficacy of 12-month denosumab treatment on bone mineral density (BMD) and bone turnover markers (BTMs) between treatment-naïve osteoporosis patients with rheumatoid arthritis (RA) and those with previous bisphosphonate (BP) therapy. Methods A total of 36 RA patients with osteoporosis completed 12-month follow-up. Twenty-five patients were osteoporotic treatment-naïve (naïve group), and 11 patients were previously treated with BPs (switch group) (average 7.9 years). BMD and BTMs were measured before and 6 and 12 months after treatment. Results BTM levels were higher in the naïve group at baseline. However, the same level of suppression was achieved at 6 months in both groups. Spine BMD increased significantly in both groups. There was no significant difference in the mean percent changes of BMD of the spine (naïve group: 6.8 ± 0.8, switch group: 5.1 ± 1.5), femoral neck (2.9 ± 1.4, 2.9 ± 1.3), and total hip (1.7 ± 0.9, 1.4 ± 1.1) between these two groups at 12 months. Conclusions The effects of denosumab on BMD and BTMs of the switch group after long-term BP treatment are comparable to those of the naïve group in RA patients. Thus, switching BPs to denosumab is one of the useful options to treat osteoporosis with RA.

【 授权许可】

Unknown